SINT SINTX TECHNOLOGIES INC.

SINTX Technologies Announces Publication of Study Confirming Superior Performance of Silicon Nitride in Cervical Spine Fusion

SINTX Technologies Announces Publication of Study Confirming Superior Performance of Silicon Nitride in Cervical Spine Fusion

SALT LAKE CITY, Utah, March 19, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced ceramics for medical device and technical applications, announced today the publication of a new peer-reviewed study demonstrating the biomechanical advantages of silicon nitride in anterior cervical discectomy and fusion (ACDF) procedures.

The study, titled Biomechanical Evaluation of Cervical Interbody Fusion Cages for Anterior Cervical Discectomy and Fusion With Variations in Morphology, was conducted by researchers at SRM Institute of Science and Technology in collaboration with SINTX Technologies. Using finite element analysis, the study compared various cage designs and materials used in cervical spine fusion procedures. The results highlight silicon nitride’s superior biomechanical performance, particularly in reducing implant subsidence, improving load distribution, and enhancing spinal stability.

Key Commercial Findings for Spinal Medical Devices

The findings of this study complement key conclusions from previous studies of the silicon nitride biomaterial and reinforce the unique advantages of silicon nitride over traditional spinal implant biomaterials like PEEK (polyetheretherketone) and titanium, including:

  • Reduced Cage Subsidence – Silicon nitride exhibited exceptional load-bearing capability, minimizing the risk of implant subsidence, a common complication in spinal fusion surgery.
  • Improved Biomechanical Stability – The study confirmed that silicon nitride interbody fusion cages provide enhanced stress distribution and reduce the risk of adjacent segment degeneration.
  • Superior Osseointegration – Unlike PEEK, which is biologically inert and can induce formation of scar tissue at the implant interface, silicon nitride promotes stronger bone fusion due to its osteoconductive and antimicrobial properties.
  • Enhanced Imaging and Safety – Unlike metal implants, silicon nitride offers radiolucency, enabling better post-surgical imaging and reducing artifacts in MRI and CT scans.

Implications for the Spinal Implant Market

“This study provides more compelling evidence of the biomechanical and clinical benefits of silicon nitride for spinal fusion applications,” said Eric Olson, CEO of SINTX Technologies. “As the demand for advanced spinal implants grows, we believe our proprietary silicon nitride biomaterial presents a transformative solution for improving long-term patient outcomes while reducing surgical complications.”

With global spinal fusion procedures expected to surpass $10 billion annually, the integration of silicon nitride into commercial spinal implant systems represents a significant market opportunity for SINTX. The company continues to engage with strategic partners to drive adoption of silicon nitride-based medical devices, including cervical interbody fusion cages and other orthopedic applications.

For more information, please visit

About SINTX Technologies, Inc.

Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter into new markets. For more information on SINTX Technologies or its materials platform, visit .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy,” "future," "likely," "may," "should," "will" and similar references to future periods.

Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in commercializing ceramic technologies and development of new product opportunities. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 27, 2024, and in SINTX’s other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law.

Business and Media Inquiries for SINTX:

SINTX Technologies

801.839.3502



EN
19/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SINTX TECHNOLOGIES INC.

 PRESS RELEASE

SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expa...

SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX T...

 PRESS RELEASE

SINTX Technologies to Participate in Noble Capital Markets’ Emerging G...

SINTX Technologies to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on February 4–5 SALT LAKE CITY, Utah, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company focused on silicon-nitride-based medical technologies, today announced that its management team will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, to be held February 4–5, 2026. The Company’s participation comes at an important stage in its evolution, following a period o...

 PRESS RELEASE

SINTX Technologies to Participate in Sidoti & Company Investor Confere...

SINTX Technologies to Participate in Sidoti & Company Investor Conference SALT LAKE CITY, Utah, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), today announced that management will be presenting at Sidoti & Company’s Year End Virtual Investor Conference, held December 10-11, 2025. Sidoti's Year End Virtual Investor ConferenceDates: December 10-11, 2025Presentation Date and Time: Wednesday, December 10, 2025 at 3:15 P.M. ETWebcast: To schedule a one-on-one meeting with SINTX Technologies’ management team, please email KCSA Strategic ...

 PRESS RELEASE

シンテックス・テクノロジーズ、AI支援型3Dプリント患者特異的インプラント向け窒化ケイ素-PEEK複合材を製造する供給契約をエボニックと締結

シンテックス・テクノロジーズ、AI支援型3Dプリント患者特異的インプラント向け窒化ケイ素-PEEK複合材を製造する供給契約をエボニックと締結 この画期的な契約により、SiN/PEEKカスタムデバイスの即時生産が可能になる ユタ州ソルトレイクシティ発 , Dec. 02, 2025 (GLOBE NEWSWIRE) -- 先進セラミックスおよびバイオマテリアル企業であるシンテックス・テクノロジーズ (SINTX Technologies, Inc.)(NASDAQ: SINT)(以下「SINTX」または「同社」) は本日、高性能ポリマー分野の世界的リーダーであるエボニック (以下「エボニック」)と供給契約を締結したことを発表した。シンテックスの米国生産施設に既に設置されている設備を用いて生産される、患者特異的インプラントのAI支援付加製造向けに設計された、同社独自の窒化ケイ素-PEEK複合材 (SiN/PEEK) (米国特許第10,806,831号) を製造するために使用される。 本契約に基づき、エボニックは商業規模の生産能力を活用してシンテックスの仕様に準拠したSiN/PEEK複合材を製造し、同社はAI設計による3Dプリント式患者特異的インプラントの製造を直ちに開始できるようになる。 シンテックスでは、脊椎腫瘍切除後の整形外科・脳神経外科腫瘍患者のための椎体置換 (...

 PRESS RELEASE

SINTX Technologies, AI 적용한 3D 프린팅 환자 맞춤형 임플란트 위한 실리콘 나이트라이드–PEEK 복합소재 ...

SINTX Technologies, AI 적용한 3D 프린팅 환자 맞춤형 임플란트 위한 실리콘 나이트라이드–PEEK 복합소재 제조 위해 EVONIK과 계약 체결 SiN/PEEK 맞춤 장비 생산에 즉시 착수할 수 있게 돼 미국 유타주 솔트레이크시티, Dec. 02, 2025 (GLOBE NEWSWIRE) -- 첨단 세라믹과 생체소재 회사인 SINTX Technologies, Inc.(나스닥명: SINT) (이하 “SINTX” 또는 “회사”)가 특허를 획득한 실리콘 나이트라이드-PEEK 복합소재(SiN/PEEK) (미국 특허 제10,806,831호)를 제조하기 위해 고성능 폴리머 분야의 글로벌 선도 기업 Evonik Corporation(“EVONIK”)과 공급 계약을 체결했다. 이 소재는 SINTX의 미국 생산 설비에 이미 설치된 장비를 활용하고 AI를 적용해 생산될 예정인 환자 맞춤형 임플란트의 적층 제조를 위해 설계되었다. 이 계약에 따라 EVONIK은 상업 규모의 생산 역량을 활용해 Sin/PEEK 복합소재를 생산하게 되며, 이에 따라 회사는 AI 설계를 바탕으로 3D 프린팅한 환자 맞춤형 임플란트 제조를 즉시 시작할 수 있게 되었다. SIN...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch